Immune functions of glia and neurons in the central nervous system

Current Immunology Reviews

Volumn 6, Issue 3, 2010, Pages 160-166

  Tian, Li ^a   Rauvala, Heikki ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Adaptive immunity; Astrocyte; Innate immunity; Microglia; Neuroinflammation; Neuron

Indexed keywords

CELL SURFACE RECEPTOR;

ADAPTIVE IMMUNITY; CELL FUNCTION; CENTRAL NERVOUS SYSTEM; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; MICROGLIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

EID: 77958064595     PISSN: 15733955     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339510791823817     Document Type: Review

References (80)

1. Frijns CJ, Kappelle LJ. Inflammatory cell adhesion molecules in ischemic cerebrovascular disease. Stroke 2002; 33: 2115-22.
2. Minghetti L. Role of inflammation in neurodegenerative diseases. Curr Opin Neurol 2005; 18: 315-21.
3. Vezzani A, Granata T. Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia 2005; 46: 1724-43.
4. Klegeris A, McGeer EG, McGeer PL. Therapeutic approaches to inflammation in neurodegenerative disease. Curr Opin Neurol 2007; 20: 351-7.
5. Muller N. Inflammation and the glutamate system in schizophrenia: implications for therapeutic targets and drug development. Expert Opin Ther Targets 2008; 12: 1497-507.
6. Steinman L. A molecular trio in relapse and remission in multiple sclerosis. Nat Rev Immunol 2009; 9: 440-7.
7. Carson MJ, Doose JM, Melchior B, Schmid CD, Ploix CC. CNS immune privilege: hiding in plain sight. Immunol Rev 2006; 213: 48-65.
8. Galea I, Bechmann I, Perry VH. What is immune privilege (not)? Trends Immunol 2007; 28: 12-8.
9. Bailey SL, Carpentier PA, McMahon EJ, Begolka WS, Miller SD. Innate and adaptive immune responses of the central nervous system. Crit Rev Immunol 2006; 26: 149-88.
10. Hohlfeld R, Kerschensteiner M, Meinl E. Dual role of inflammation in CNS disease. Neurology 2007; 68: S58-63; discussion S91-6.
11. Perry VH. The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease. Brain Behav Immun 2004; 18: 407-13.
12. Godbout JP, Chen J, Abraham J, et al. Exaggerated neuroinflammation and sickness behavior in aged mice following activation of the peripheral innate immune system. FASEB J 2005; 19: 1329-31.
13. Rivest S. Regulation of innate immune responses in the brain. Nat Rev Immunol 2009; 9: 429-39.
14. Tambuyzer BR, Ponsaerts P, Nouwen EJ. Microglia: gatekeepers of central nervous system immunology. J Leukoc Biol 2009; 85: 352-70.
15. Griffiths MR, Gasque P, Neal JW. The multiple roles of the innate immune system in the regulation of apoptosis and inflammation in the brain. J Neuropathol Exp Neurol 2009; 68: 217-26.
16. Bessis A, Bechade C, Bernard D, Roumier A. Microglial control of neuronal death and synaptic properties. Glia 2007; 55: 233-8.
17. Napoli I, Neumann H. Microglial clearance function in health and disease. Neuroscience 2009; 158: 1030-8.
18. Perry VH, O'Connor V. C1q: the perfect complement for a synaptic feast? Nat Rev Neurosci 2008; 9: 807-11.
19. Stevens B, Allen NJ, Vazquez LE, et al. The classical complement cascade mediates CNS synapse elimination. Cell 2007; 131: 1164-78.
20. Becher B, Bechmann I, Greter M. Antigen presentation in autoimmunity and CNS inflammation: how T lymphocytes recognize the brain. J Mol Med 2006; 84: 532-43.
21. Haydon PG, Carmignoto G. Astrocyte control of synaptic transmission and neurovascular coupling. Physiol Rev 2006; 86: 1009-31.
22. Bechmann I, Galea I, Perry VH. What is the blood-brain barrier (not)? Trends Immunol 2007; 28: 5-11.
23. Farina C, Aloisi F, Meinl E. Astrocytes are active players in cerebral innate immunity. Trends Immunol 2007; 28: 138-45.
24. Engelhardt B. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines. J Neurol Sci 2008; 274: 23-6.
25. Schwab C, McGeer PL. Inflammatory aspects of Alzheimer disease and other neurodegenerative disorders. J Alzheimers Dis 2008; 13: 359-69.
26. Nair A, Frederick TJ, Miller SD. Astrocytes in multiple sclerosis: a product of their environment. Cell Mol Life Sci 2008; 65: 2702-20.
27. Wyss-Coray T, Loike JD, Brionne TC, et al. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat Med 2003; 9: 453-7.
28. Tan L, Gordon KB, Mueller JP, Matis LA, Miller SD. Presentation of proteolipid protein epitopes and B7-1-dependent activation of encephalitogenic T cells by IFN-gamma-activated SJL/J astrocytes. J Immunol 1998; 160: 4271-9.
29. Soos JM, Morrow J, Ashley TA, Szente BE, Bikoff EK, Zamvil SS. Astrocytes express elements of the class II endocytic pathway and process central nervous system autoantigen for presentation to encephalitogenic T cells. J Immunol 1998; 161: 5959-66.
30. Aloisi F, Ria F, Penna G, Adorini L. Microglia are more efficient than astrocytes in antigen processing and in Th1 but not Th2 cell activation. J Immunol 1998; 160: 4671-80.
31. Karpus WJ, Kennedy KJ. MIP-1alpha and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1/Th2 lymphocyte differentiation. J Leukoc Biol 1997; 62: 681-7.
32. Gimsa U, ORen A, Pandiyan P, et al. Astrocytes protect the CNS: antigen-specific T helper cell responses are inhibited by astrocyteinduced upregulation of CTLA-4 (CD152). J Mol Med 2004; 82: 364-72.
33. Trajkovic V, Vuckovic O, Stosic-Grujicic S, et al. Astrocyteinduced regulatory T cells mitigate CNS autoimmunity. Glia 2004; 47: 168-79.
34. Meiron M, Zohar Y, Anunu R, Wildbaum G, Karin N. CXCL12 (SDF-1alpha) suppresses ongoing experimental autoimmune encephalomyelitis by selecting antigen-specific regulatory T cells. J Exp Med 2008; 205: 2643-55.
35. Biber K, Neumann H, Inoue K, Boddeke HW. Neuronal 'On' and 'Off' signals control microglia. Trends Neurosci 2007; 30: 596-602.
36. Tian L, Rauvala H, Gahmberg CG. Neuronal regulation of immune responses in the central nervous system. Trends Immunol 2009; 30: 91-9.
37. Sternberg EM. Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nat Rev Immunol 2006; 6: 318-28.
38. Tracey KJ. Reflex control of immunity. Nat Rev Immunol 2009; 9: 418-28.
39. Wahl SM, Wen J, Moutsopoulos N. TGF-beta: a mobile purveyor of immune privilege. Immunol Rev 2006; 213: 213-27.
40. Kerschensteiner M, Meinl E, Hohlfeld R. Neuro-immune crosstalk in CNS diseases. Neuroscience 2009; 158: 1122-32.
41. Reinke E, Fabry Z. Breaking or making immunological privilege in the central nervous system: the regulation of immunity by neuropeptides. Immunol Lett 2006; 104: 102-9.
42. Boche D, Cunningham C, Docagne F, Scott H, Perry VH. TGFbeta1 regulates the inflammatory response during chronic neurodegeneration. Neurobiol Dis 2006; 22: 638-50.
43. Brionne TC, Tesseur I, Masliah E, Wyss-Coray T. Loss of TGFbeta 1 leads to increased neuronal cell death and microgliosis in mouse brain. Neuron 2003; 40: 1133-45.
44. Harrison JK, Jiang Y, Chen S, et al. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci USA 1998; 95: 10896-901.
45. Cardona AE, Pioro EP, Sasse ME, et al. Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci 2006; 9: 917-24.
46. Bespalov MM, Saarma M. GDNF family receptor complexes are emerging drug targets. Trends Pharmacol Sci 2007; 28: 68-74.
47. Neumann H, Misgeld T, Matsumuro K, Wekerle H. Neurotrophins inhibit major histocompatibility class II inducibility of microglia: involvement of the p75 neurotrophin receptor. Proc Natl Acad Sci USA 1998; 95: 5779-84.
48. Wei R, Jonakait GM. Neurotrophins and the anti-inflammatory agents interleukin-4 (IL-4), IL-10, IL-11 and transforming growth factor-beta1 (TGF-beta1) down-regulate T cell co-stimulatory molecules B7 and CD40 on cultured rat microglia. J Neuroimmunol 1999; 95: 8-18.
49. Delgado M, Varela N, Gonzalez-Rey E. Vasoactive intestinal peptide protects against beta-amyloid-induced neurodegeneration by inhibiting microglia activation at multiple levels. Glia 2008; 56: 1091-103.
50. Bjurstom H, Wang J, Ericsson I, et al. GABA, a natural immunomodulator of T lymphocytes. J Neuroimmunol 2008; 205: 44-50.
51. Tan J, Town T, Mori T, et al. CD45 opposes beta-amyloid peptideinduced microglial activation via inhibition of p44/42 mitogenactivated protein kinase. J Neurosci 2000; 20: 7587-94.
52. Mott RT, Ait-Ghezala G, Town T, et al. Neuronal expression of CD22: novel mechanism for inhibiting microglial proinflammatory cytokine production. Glia 2004; 46: 369-79.
53. Oldenborg PA, Gresham HD, Lindberg FP. CD47-signal regulatory protein alpha (SIRPalpha) regulates Fcgamma and complement receptor-mediated phagocytosis. J Exp Med 2001; 193: 855-62.
54. Smith RE, Patel V, Seatter SD, et al. A novel MyD-1 (SIRP-1alpha) signaling pathway that inhibits LPS-induced TNFalpha production by monocytes. Blood 2003; 102: 2532-40.
55. Hoek RM, Ruuls SR, Murphy CA, et al. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 2000; 290: 1768-71.
56. Meuth SG, Simon OJ, Grimm A, et al. CNS inflammation and neuronal degeneration is aggravated by impaired CD200-CD200Rmediated macrophage silencing. J Neuroimmunol 2008; 194: 62-9.
57. McMillian MK, Thai L, Hong JS, O'Callaghan JP, Pennypacker KR. Brain injury in a dish: a model for reactive gliosis. Trends Neurosci 1994; 17: 138-42.
58. Chang RC, Hudson P, Wilson B, Haddon L, Hong JS. Influence of neurons on lipopolysaccharide-stimulated production of nitric oxide and tumor necrosis factor-alpha by cultured glia. Brain Res 2000; 853: 236-44.
59. Minghetti L, Ajmone-Cat MA, De Berardinis MA, De Simone R. Microglial activation in chronic neurodegenerative diseases: roles of apoptotic neurons and chronic stimulation. Brain Res Brain Res Rev 2005; 48: 251-6.
60. Majed HH, Chandran S, Niclou SP, et al. A novel role for Sema3A in neuroprotection from injury mediated by activated microglia. J Neurosci 2006; 26: 1730-8.
61. Polazzi E, Contestabile A. Overactivation of LPS-stimulated microglial cells by co-cultured neurons or neuron-conditioned medium. J Neuroimmunol 2006; 172: 104-11.
62. Takahashi K, Rochford CD, Neumann H. Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med 2005; 201: 647-57.
63. Tian L, Lappalainen J, Autero M, Hanninen S, Rauvala H, Gahmberg CG. Shedded neuronal ICAM-5 suppresses T-cell activation. Blood 2008; 111: 3615-25.
64. Lepelletier Y, Moura IC, Hadj-Slimane R, et al. Immunosuppressive role of semaphorin-3A on T cell proliferation is mediated by inhibition of actin cytoskeleton reorganization. Eur J Immunol 2006; 36: 1782-93.
65. Catalano A, Caprari P, Moretti S, Faronato M, Tamagnone L, Procopio A. Semaphorin-3A is expressed by tumor cells and alters T-cell signal transduction and function. Blood 2006; 107: 3321-29.
66. Czopik AK, Bynoe MS, Palm N, Raine CS, Medzhitov R. Semaphorin 7A is a negative regulator of T cell responses. Immunity 2006; 24: 591-600.
67. Yamamoto M, Suzuki K, Okuno T, et al. Plexin-A4 negatively regulates T lymphocyte responses. Int Immunol 2008; 20: 413-20.
68. Liu Y, Teige I, Birnir B, Issazadeh-Navikas S. Neuron-mediated generation of regulatory T cells from encephalitogenic T cells suppresses EAE. Nat Med 2006; 12: 518-25.
69. Bynoe MS, Bonorino P, Viret C. Control of experimental autoimmune encephalomyelitis by CD4+ suppressor T cells: peripheral versus in situ immunoregulation. J Neuroimmunol 2007; 191: 61-9.
70. Ethell DW, Buhler LA. Fas ligand-mediated apoptosis in degenerative disorders of the brain. J Clin Immunol 2003; 23: 439-46.
71. Choi C, Benveniste EN. Fas ligand/Fas system in the brain: regulator of immune and apoptotic responses. Brain Res Brain Res Rev 2004; 44: 65-81.
72. Wildbaum G, Westermann J, Maor G, Karin N. A targeted DNA vaccine encoding fas ligand defines its dual role in the regulation of experimental autoimmune encephalomyelitis. J Clin Invest 2000; 106: 671-9.
73. Beier CP, Wischhusen J, Gleichmann M, et al. FasL (CD95L/APO-1L) resistance of neurons mediated by phosphatidylinositol 3-kinase-Akt/protein kinase B-dependent expression of lifeguard/neuronal membrane protein 35. J Neurosci 2005; 25: 6765-74.
74. Song JH, Bellail A, Tse MC, Yong VW, Hao C. Human astrocytes are resistant to Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. J Neurosci 2006; 26: 3299-308.
75. Rauvala H, Rouhiainen A. RAGE as a receptor of HMGB1 (Amphoterin): roles in health and disease. Curr Mol Med 2007; 7: 725-34.
76. Okun E, Griffioen KJ, Lathia JD, Tang SC, Mattson MP, Arumugam TV. Toll-like receptors in neurodegeneration. Brain Res Rev 2009; 59: 278-92.
77. Boulanger LM, Shatz CJ. Immune signalling in neural development, synaptic plasticity and disease. Nat Rev Neurosci 2004; 5: 521-31.
78. Candelario-Jalil E, Yang Y, Rosenberg GA. Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience 2009; 158: 983-94.
79. Rauch U. Extracellular matrix components associated with remodeling processes in brain. Cell Mol Life Sci 2004; 61: 2031-45.
80. Ma Q, Cornelli U, Hanin I, et al. Heparin oligosaccharides as potential therapeutic agents in senile dementia. Curr Pharm Des 2007; 13: 1607-16.